TrialPath
Alzheimer's disease · Boston

Alzheimer's disease clinical trials in Boston

20 recruiting alzheimer disease studies within range of Boston. Click any trial for full eligibility criteria and contact info.

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

NCT07236190 · Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Recruiting

This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology

PhasePhase 2
TypeInterventional
Age55 Years
WhereBoston, Massachusetts, United States
SponsorMassachusetts General Hospital
▾Tap for details
Apply

Alzheimer's Tau Platform: Master Protocol

Recruiting

The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. This platform trial allows for the simultaneous testing of multiple tau therapies under a shared master protocol. This means that multiple investigational products will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. The main questions the platform trial aims to answer are: * Does a tau-directed therapy, alone or in combination with donanemab, reduce tau buildup in the brain compared to donanemab alone? * Does a tau-directed therapy, alone or in combination with donanemab, slow disease progression based on brain imaging, fluid biomarkers, and measures of memory and thinking? Participants will: * Be randomized to a treatment regimens, each containing different tau therapies. The exact number of treatment regimens that will active at the time of screening will change over time. * Receive donanemab or placebo for 6 months, followed by 24 months of tau therapy alone or in combination with donanemab. * Undergo regular cognitive testing, brain scans (MRI/PET), and biomarker assessments over 30 months Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to one of three arms: (1) tau therapy alone, (2) a combination of donanemab and tau therapy, or (3) donanemab alone. New regimens will be continuously added as new investigational products become available. The Alzheimer's Tau Platform Trial will enroll additional participants as each new regimen becomes available. ATP will launch with one regimen: Regimen A: AADvac1. In the future, Regimen B ("Tau2") will launch with a second tau directed therapy.

PhasePhase 2
TypeInterventional
Age50 Years – 80 Years
WherePhoenix, Arizona, United States + 6 more
SponsorPaul S. Aisen
▾Tap for details
Apply

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106 · Amyloid Plaque, Beta-Amyloid, DSAD
Recruiting

The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

PhasePhase 1 / Phase 2
TypeInterventional
Age35 Years – 85 Years
WherePhoenix, Arizona, United States + 25 more
SponsorAC Immune SA
▾Tap for details
Apply

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

NCT07717411 · Alzheimer's Disease
Recruiting

This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

PhasePhase 3
TypeInterventional
Age55 Years – 80 Years
WhereIrvine, California, United States + 71 more
SponsorHoffmann-La Roche
▾Tap for details
Apply

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

NCT07688213 · Dementia, Alzheimer's Type, Alzheimer's Disease
Recruiting

This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology. This Phase 2 study has 2 parts: Part A is a randomized, double-blind, parallel-group, placebo-controlled study with SAR448851 oral once daily. Part B is an open-label extension. All participants who complete Part A may continue to Part B. An optional dose 2 cohort will be considered to evaluate the efficacy and safety of SAR448851 dose 2 oral once daily. The study duration will be up to 111 weeks for Part A and B, and up to 63 weeks for the dose 2 cohort. The treatment duration will be up to 96 weeks for Part A and B, and up to 48 weeks for the dose 2 cohort. Up to 160 participants will be included in this study.

PhasePhase 2
TypeInterventional
Age55 Years – 85 Years
WhereLong Beach, California, United States + 31 more
SponsorSanofi
▾Tap for details
Apply

Cognitive Neurology Unit Clinical Registry

NCT05925621 · Alzheimer Disease
Recruiting

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

Phase—
TypeObservational
Age50 Years – 95 Years
WhereBoston, Massachusetts, United States
SponsorBeth Israel Deaconess Medical Center
▾Tap for details
Apply

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

Recruiting

This phase 2a study will research the safety and tolerability of Foralumab, a human anti-CD3 antibody. An antibody is a molecule secreted by the immune system. These molecules are created to identify a specific pathogen. Previous data on experimental mice has suggested that Foralumab increases the immune system activity in the brain to reduce the inflammation of microglia, the brain's main immune cells. This combination of increased immune reactivity and less microglia inflammation may improve the immune response throughout the brain. Alzheimer's disease and other forms of dementia are characteristically known for the build-up of certain proteins in the brain. This trial will evaluate whether nasal Foralumab can improve cognition in participants with mild cognitive impairment due to early Alzheimer's or dementia. The trial will ask participants to administer Foralumab nasally three times a week for eight weeks. The administration will occur intermittently, with breaks between each dosing cycle. Participants will also receive brain scans (Amyloid PET and MRI), undergo cognitive testing, blood draws, and physical, neurological, and nasal exams. Volunteers are expected to remain in the trial for six months.

PhasePhase 2
TypeInterventional
Age60 Years – 85 Years
WhereBoston, Massachusetts, United States
SponsorBrigham and Women's Hospital
▾Tap for details
Apply

TMS for Cognitive Decline in Aging and Preclinical AD

NCT06956300 · Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging
Recruiting

In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical Alzheimer's disease. This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls cognition. Changes resulting from this stimulation will be measured with behavioral tests, as well as by taking brain images with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.

PhaseNA
TypeInterventional
Age40 Years – 99 Years
WhereBoston, Massachusetts, United States
SponsorMassachusetts General Hospital
▾Tap for details
Apply

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Recruiting

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.

PhasePhase 3
TypeInterventional
Age55 Years – 90 Years
WhereHomewood, Alabama, United States + 431 more
SponsorKaruna Therapeutics, Inc., a Bristol Myers Squibb company
▾Tap for details
Apply

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203 · Alzheimer's Disease
Recruiting

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

PhasePhase 3
TypeInterventional
Age60 Years – 85 Years
WhereFullerton, California, United States + 128 more
SponsorBristol-Myers Squibb
▾Tap for details
Apply

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895 · Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Recruiting

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.

PhasePhase 3
TypeInterventional
Age18 Years – 75 Years
WhereLa Jolla, California, United States + 103 more
SponsorEidos Therapeutics, a BridgeBio company
▾Tap for details
Apply

Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)

NCT04124029 · Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
Recruiting

This is a research study that aims to examine whether Veterans with mild Traumatic Brain Injuries are at risk for dementia by studying their memory, brain wave activity, brain structure and proteins that can be elevated after brain injury and in dementia.

Phase—
TypeObservational
Age30 Years – 90 Years
WhereBoston, Massachusetts, United States
SponsorVA Office of Research and Development
▾Tap for details
Apply

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

NCT05881239 · Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment
Recruiting

The goal of this study is to objectively test one's sense of smell, called olfaction, in participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild Behavioral Impairment (MBI), and age-matched controls. The main question it aims to answer is whether the AROMHA Brain Health Test could serve as a predictive biomarker of neurodegenerative disorders. This understanding will aid in the development of a noninvasive, cost-effective diagnostic tool that reliably and specifically distinguishes disease and normal aging populations. Participants will take the approximately 45-minute AROMHA Brain Health Smell Test where they will peel and sniff labels on the physical smell cards and answer questions on the web-based app relating to what they smelled. Participants will undergo tests for odor intensity, odor identification, odor discrimination, and episodic olfactory memory, but will not be provided the results of these tests.

Phase—
TypeObservational
Age18 Years – 100 Years
WhereBoston, Massachusetts, United States
SponsorMassachusetts General Hospital
▾Tap for details
Apply

Dominantly Inherited Alzheimer Network (DIAN)

NCT00869817 · Alzheimer's Disease
Recruiting

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Phase—
TypeObservational
Age18 Years
WhereJacksonville, Florida, United States + 25 more
SponsorWashington University School of Medicine
▾Tap for details
Apply

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352 · Alzheimers Disease
Recruiting

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

PhasePhase 3
TypeInterventional
Age50 Years – 90 Years
WhereBirmingham, Alabama, United States + 235 more
SponsorHoffmann-La Roche
▾Tap for details
Apply

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

NCT05658913 · Alzheimer's Disease
Recruiting

To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.

Phase—
TypeObservational
Age18 Years – 120 Years
WhereBoston, Massachusetts, United States + 1 more
SponsorUniversity of Pennsylvania
▾Tap for details
Apply

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

NCT07602582 · Alzheimer Disease, Dementia, Plaque, Amyloid
Recruiting

The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

PhasePhase 3
TypeInterventional
Age55 Years
WherePhoenix, Arizona, United States + 61 more
SponsorEli Lilly and Company
▾Tap for details
Apply

Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease

NCT06538311 · Alzheimer Disease, Mild Cognitive Impairment, Logopenic Progressive Aphasia
Recruiting

In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.

PhaseEARLY_Phase 1
TypeInterventional
Age40 Years – 99 Years
WhereBoston, Massachusetts, United States
SponsorMassachusetts General Hospital
▾Tap for details
Apply

Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease

NCT05776641 · Alzheimer Disease, Family Members
Recruiting

Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. A light and sound device was developed for humans that stimulates the brain at 40Hz that can be used safely at home. The goal of this study is to see if using this device can prevent dementia in people who are at risk for developing Alzheimer's disease.

PhaseNA
TypeInterventional
Age55 Years – 90 Years
WhereBoston, Massachusetts, United States + 1 more
SponsorMassachusetts General Hospital
▾Tap for details
Apply

Assess Fibrin in Brains With AD/ADRD

NCT05336695 · Alzheimer Disease, Dementia of Alzheimer Type
Recruiting

The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.

PhasePhase 1 / Phase 2
TypeInterventional
Age55 Years – 90 Years
WhereBoston, Massachusetts, United States
SponsorMassachusetts General Hospital
▾Tap for details
Apply